Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes:: a meta-analysis of 27 studies
Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes:: a meta-analysis of 27 studies
复制标题
DOI：
10.1007/s00125-003-1126-4
复制
发表时间：
2003-07-01
期刊：
影响因子：
8.2
通讯作者：
Mensink, RP
中科院分区：
文献类型：
--
作者：
Jellema, A;Zeegers, MPA;Mensink, RP
目标/假设。几项病例对照研究已经检验了 IRS-1 基因中的 Gly972Arg 变异与 2 型糖尿病之间的关联，但大多数研究的效力有限，因此结果可能相互矛盾。我们通过荟萃分析系统地回顾了文献，并调查了不同研究结果中异质性的来源。结果。基于 27 项研究的 3408 例病例和 5419 例对照病例，总结风险比为 1.25 (95% CI 1.05-1.48)。然而，根据研究类型、验证对照受试者非糖尿病状态的方法以及病例受试者的年龄，结果有所不同。基于人群的研究报告的比值比低于基于医院的研究（OR 0.98，95% CI 0.74-1.30 vs OR 1.43，95% CI 1.17-1.74）。此外，在对照受试者中排除糖尿病的诊断测试与 IRS-1 Gly972Arg 变异和 2 型糖尿病之间的关联相互作用 (p=0.03)。最后，优势比随着年龄的增加而降低（p=0.03）。结论/解释。总体而言，与非携带者相比，IRS-1 基因 972Arg 变体携带者患 2 型糖尿病的风险增加 25%。在医院研究中，优势比通常较高，包括相对年轻、有症状的病例。
Aims/hypothesis. Several case-control studies have examined the association between the Gly972Arg variant in the IRS-1 gene and Type 2 diabetes, but most had limited power and results could therefore be conflicting.Methods. We systematically reviewed the literature by means of a meta-analysis and investigated sources of heterogeneity in results of different studies.Results. The summary risk ratio, based on 3408 cases and 5419 control cases from 27 studies, was 1.25 (95% CI 1.05-1.48). The results, however, differed according to the type of study, method of verifying non-diabetic status of the control subjects, and age of the case subjects. Population-based studies reported lower odds ratios than hospital-based studies (OR 0.98, 95% CI 0.74-1.30 vs OR 1.43, 95% CI 1.17-1.74). Also, the diagnostic test to exclude diabetes amongst control subjects interacted with the association between the IRS-1 Gly972Arg variant and Type 2 diabetes (p=0.03). Finally, the odds ratio reduced with increasing age (p=0.03).Conclusion/interpretation. Overall, carriers of the 972Arg variant of the IRS-1 gene are at a 25% increased risk of having Type 2 diabetes compared with non-carriers. The odds ratios are generally higher in hospital-based studies, including relatively young, symptomatic, cases.